Rosuvastatin Impurity Profile and Lactone Impurity: Structure, Pharmacopoeial Limits and Reference Standard Selection

2026-05-29 · CATO · CATO Standards

Rosuvastatin calciumis one of the most potent lipid-lowering statins, reducing hepatic cholesterol synthesis through competitive inhibition of HMG-CoA reductase and widely used for hypercholesterolemia and primary prevention of cardiovascular events. The global market has stabilized above USD 3 billion, and more than 40 generic companies in China have passed evaluation, making competition extremely intense.

Against this background, precise control of the impurity profile has become a "hard indicator" of generic drug quality consistency evaluation — and the impurity system of rosuvastatin is precisely one of the most complex among statins.

Rosuvastatin Calcium

CAS No.:147098-20-2

1. Main Impurity Profile of Rosuvastatin: The Full Chain from Process to Degradation

The impurities of rosuvastatin can be divided into three categories by source: process impurities, degradation impurities, and potential impurities. The known impurities listed in major pharmacopoeias are as follows:

1. Impurities listed in the European Pharmacopoeia (EP)

The EP has established related substances methods for both the rosuvastatin calcium API and its formulations, with the specified impurities including:

2. Impurities listed in the United States Pharmacopeia (USP)

The USP tablet monograph (Revision Bulletin) lists the following impurities and limits:

3. Impurities listed in Chinese regulatory standards

According to the National Medical Products Administration drug standards (YBH04162008, YBH08932008, etc.) and related literature, the related substances testing of rosuvastatin calcium API focuses on five known impurities: the oxidation product (5-oxo, corresponding to EP Impurity C), the lactone (corresponding to EP Impurity D), the diastereomer (corresponding to EP Impurity B), photodegradation product I, and photodegradation product II. Among them, photodegradation products I and II are produced by light exposure during sample handling and can be controlled by light-protected operations.

2. Focus on the Lactone Impurity: From Structure to Formation

1. Structure and key parameters

The main structure of rosuvastatin contains a typical β,δ-dihydroxycarboxylic acid side chain. Under certain conditions, the hydroxyl and carboxylic acid groups in the side chain undergo an intramolecular dehydration cyclization reaction to form a six-membered lactone ring, generating Rosuvastatin Lactone. Compared with the open-chain hydroxy acid structure of the parent drug, once the Lactone impurity forms, the carboxylic acid group is converted into a lactone ester bond, reducing molecular polarity and increasing lipophilicity; thus, in reversed-phase HPLC it typically shows prolonged retention time. This transformation is a typical reversible lactonization reaction in statins and one of the key degradation pathways in the stability study of rosuvastatin.

2. Formation mechanism

The active form of rosuvastatin is the ring-opened 3,5-dihydroxy-6-heptenoic acid side chain. The formation of the lactone impurity is an intramolecular cyclization reaction — the C-5 hydroxyl nucleophilically attacks the C-1 carboxylic acid, dehydrating and ring-closing to form a six-membered δ-lactone (tetrahydropyran-2-one structure). Key factors promoting this reaction include: acidic conditions (lactone increases most significantly under acid degradation in forced degradation), high temperature (notably elevated at 60 °C storage), low-pH formulation microenvironment (introduced by excipients or coating), and long-term storage (thermodynamically favorable, accumulating slowly at room temperature).

Notably, the lactone impurity is not only a degradation product — 0.03%–0.3% lactone can also be detected during API process optimization, so it has the dual attributes of both a degradation and a process impurity.

3. Pharmacological significance of the lactone impurity

It is worth noting that the in vivo metabolism of rosuvastatin also produces a lactone metabolite. According to the FDA-approved Crestor label, about 10% of rosuvastatin is metabolized in vivo, with the main products being the N-desmethyl metabolite and the lactone metabolite. Among them, the HMG-CoA reductase inhibitory activity of the N-desmethyl metabolite is about 1/6 to 1/2 that of the parent drug (FDA original text: "approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity"), while the lactone metabolite is considered clinically inactive. Rosuvastatin itself accounts for more than 90% of the HMG-CoA reductase inhibitory activity in plasma. Therefore, the presence of the lactone impurity in a drug product not only represents a loss of active ingredient but is also a direct indicator of drug product stability deterioration.

In addition, some studies suggest that the lactone forms of statins, being more lipophilic, penetrate muscle cells more readily and may be associated with statin-induced myotoxicity (SIM). However, it should be noted that this mechanism is mainly derived from studies of lipophilic statins (simvastatin, atorvastatin) — simvastatin and lovastatin are themselves administered as lactone prodrugs, and their CYP3A4 metabolic pathway is a major source of drug interactions. Rosuvastatin is a hydrophilic statin metabolized mainly by CYP2C9 (with a minor contribution from CYP2C19) and not significantly by CYP3A4, so the explanatory power of the above lactone-myotoxicity association for rosuvastatin is limited. Nevertheless, from the perspective of drug quality control, strict control of the lactone impurity in the API and formulations remains necessary.

3. Lactone Impurity Limits in Various Pharmacopoeias

Different pharmacopoeias have different limits for the rosuvastatin lactone impurity, and the standards for the API and formulations also differ. The following is a comparison of the limits in major pharmacopoeias:

1. Drug Substance

2. Drug Product / Tablets

Solution: CATO Complete Rosuvastatin Impurity Reference Standards

Guangzhou CATO Research Chemicals Co., Ltd. is an ISO 17034-certified reference material producer with dual CNAS + ANAB accreditation, specializing in the R&D and production of pharmaceutical impurity reference standards.

CATO provides a complete set of rosuvastatin API impurity reference standards, covering all specified impurities and major degradation impurities listed in the EP, USP, and Chinese Pharmacopoeia standards, including:

Rosuvastatin lactone (EP Impurity D, CAS 503610-43-3)
5-Oxo rosuvastatin (EP Impurity C / USP Rosuvastatin ketone, CAS 1422619-13-3)
Rosuvastatin diastereomer (EP Impurity B, CAS 1007912-86-8)
Rosuvastatin ethyl ester (EP FP-A, CAS 851443-04-4)
Rosuvastatin EP Impurity A / USP Related Compound A (CAS 1714147-47-3 calcium salt)
Rosuvastatin EP Impurity E / USP Related Compound B (CAS 2226413-61-0)
and more process impurities and degradation impurities…

Rosuvastatin impurity control is a systematic undertaking involving the synthetic process, formulation, storage conditions, and analytical methods. Among them, the lactone impurity (EP Impurity D), as the most critical degradation/process impurity, has a clearly defined chemical mechanism and environmental dependence, and is strictly controlled as a specified impurity in all national pharmacopoeias.

For generic drug companies, precise impurity profile studies are not only a mandatory requirement of consistency evaluation but also a core embodiment of product quality competitiveness. Choosing impurity reference standards with fully confirmed structures, traceable value-assignment methods, and comprehensive regulatory coverage is the first step to ensuring accurate and compliant related substances testing.